1066 related articles for article (PubMed ID: 27732787)
1. Nonalcoholic Steatohepatitis.
Suzuki A; Diehl AM
Annu Rev Med; 2017 Jan; 68():85-98. PubMed ID: 27732787
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.
Schwabe RF; Tabas I; Pajvani UB
Gastroenterology; 2020 May; 158(7):1913-1928. PubMed ID: 32044315
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis and non-alcoholic fatty liver diseases.
Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
Pierantonelli I; Svegliati-Baroni G
Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
Farrell GC; Haczeyni F; Chitturi S
Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
[TBL] [Abstract][Full Text] [Related]
6. p16 deficiency promotes nonalcoholic steatohepatitis via regulation of hepatic oxidative stress.
Lv F; Wu J; Miao D; An W; Wang Y
Biochem Biophys Res Commun; 2017 Apr; 486(2):264-269. PubMed ID: 28286271
[TBL] [Abstract][Full Text] [Related]
7. Deletion of Smad4 reduces hepatic inflammation and fibrogenesis during nonalcoholic steatohepatitis progression.
Qin G; Wang GZ; Guo DD; Bai RX; Wang M; Du SY
J Dig Dis; 2018 May; 19(5):301-313. PubMed ID: 29696816
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.
Wang X; Zheng Z; Caviglia JM; Corey KE; Herfel TM; Cai B; Masia R; Chung RT; Lefkowitch JH; Schwabe RF; Tabas I
Cell Metab; 2016 Dec; 24(6):848-862. PubMed ID: 28068223
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
Ibrahim SH; Hirsova P; Gores GJ
Gut; 2018 May; 67(5):963-972. PubMed ID: 29367207
[TBL] [Abstract][Full Text] [Related]
10. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
11. Lipid mediators of liver injury in nonalcoholic fatty liver disease.
Liangpunsakul S; Chalasani N
Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G75-G81. PubMed ID: 30383414
[TBL] [Abstract][Full Text] [Related]
12. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of Nonalcoholic Steatohepatitis.
Machado MV; Diehl AM
Gastroenterology; 2016 Jun; 150(8):1769-77. PubMed ID: 26928243
[TBL] [Abstract][Full Text] [Related]
14. Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis.
Saito K; Uebanso T; Maekawa K; Ishikawa M; Taguchi R; Nammo T; Nishimaki-Mogami T; Udagawa H; Fujii M; Shibazaki Y; Yoneyama H; Yasuda K; Saito Y
Sci Rep; 2015 Aug; 5():12466. PubMed ID: 26289793
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on Treatment for Nonalcoholic Steatohepatitis.
Lassailly G; Caiazzo R; Pattou F; Mathurin P
Gastroenterology; 2016 Jun; 150(8):1835-48. PubMed ID: 26971824
[TBL] [Abstract][Full Text] [Related]
16. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
17. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis.
Dornas W; Lagente V
Pharmacol Res; 2019 Mar; 141():418-428. PubMed ID: 30658094
[TBL] [Abstract][Full Text] [Related]
18. Nobiletin mitigates hepatocytes death, liver inflammation, and fibrosis in a murine model of NASH through modulating hepatic oxidative stress and mitochondrial dysfunction.
Li S; Li X; Chen F; Liu M; Ning L; Yan Y; Zhang S; Huang S; Tu C
J Nutr Biochem; 2022 Feb; 100():108888. PubMed ID: 34695558
[TBL] [Abstract][Full Text] [Related]
19. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
20. Myeloperoxidase-Hepatocyte-Stellate Cell Cross Talk Promotes Hepatocyte Injury and Fibrosis in Experimental Nonalcoholic Steatohepatitis.
Pulli B; Ali M; Iwamoto Y; Zeller MW; Schob S; Linnoila JJ; Chen JW
Antioxid Redox Signal; 2015 Dec; 23(16):1255-69. PubMed ID: 26058518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
